Role of the Intrapartum Grobman Nomogram in the Indication of Attempted Vaginal Delivery After Cesarean Section
Launched by CENTRAL HOSPITAL, NANCY, FRANCE · Jan 1, 2024
Trial Information
Current as of July 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial aims to understand how well a tool called the Grobman nomogram can help predict whether women with a history of cesarean sections can safely attempt a vaginal delivery. As more women choose to have cesarean births, it's important to find reliable ways to assess the risks and benefits of trying for a vaginal birth in future pregnancies. This study will take place at Nancy University Hospital and will focus on providing valuable information for healthcare providers and expecting mothers.
To participate in this trial, women must be pregnant with one baby (not twins), be at least 37 weeks along in their pregnancy, and have had a previous cesarean delivery. Unfortunately, those who have experienced a fetal loss will not be eligible. If you qualify and choose to participate, you can expect to help researchers better understand the potential for vaginal deliveries after a cesarean section, which could lead to safer options for women in the future.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Vertex singleton pregnancy
- • Full-term delivery (beyond 37 weeks)
- • A history of cesarean section (segmental transverse scar)
- Exclusion Criteria:
- • Fetal death in utero
About Central Hospital, Nancy, France
Central Hospital, located in Nancy, France, is a leading healthcare institution dedicated to advancing medical research and improving patient outcomes. As a prominent clinical trial sponsor, the hospital is committed to conducting innovative studies across various therapeutic areas, fostering collaboration among multidisciplinary teams of healthcare professionals and researchers. With a strong emphasis on ethical standards and patient safety, Central Hospital leverages its state-of-the-art facilities and expertise to contribute to the development of cutting-edge treatments and enhance the overall quality of care within the community and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nancy, , France
Patients applied
Trial Officials
Charlotte COTTEZ
Study Director
Hospital, Nancy, France
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported